In compliance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 2, 2025, Samrat Pharmachem has informed that it enclosed the Integrated Filing (Financial) for the Quarter and nine months ended December 31, 2024. A. Financial Results Enclosed. B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc - Not Applicable. C. Format for disclosing outstanding default on loans and debt securities - Not Applicable. D. Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - Not Applicable. E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th Quarter) - Not Applicable. The above information is available on the website of the Company: www.samratpharmachem.com.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1735.45 |
Dr. Reddys Lab | 1144.05 |
Cipla | 1441.70 |
Lupin | 2026.50 |
Zydus Lifesciences | 885.70 |
View more.. |